Ignite Creation Date:
2024-05-06 @ 3:07 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04522817
Status:
WITHDRAWN
Last Update Posted:
2020-12-17
First Post:
2020-08-20
Brief Title:
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
Sponsor:
Lisata Therapeutics Inc
Organization:
Lisata Therapeutics Inc
Study Overview
Official Title:
CLBS119 Autologous Peripheral Blood Derived CD34 Cells for Repair of COVID-19 Induced Pulmonary Damage
Status:
WITHDRAWN
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Acute COVID-19 treatments have improved significantly leading to decreased use of ventilatory support This coupled with approval of a vaccine has changed the profileprognosis of patients and led to a lack of patients with long-term hypoxia
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults
Detailed Description:
This open-label clinical trial will explore the safety and potential efficacy of peripheral blood derived autologous CD34 cells for the repair of COVID-19 induced pulmonary damage in adults Eligible subjects will receive a single administration of CLBS119
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None